NCT00144703View on ClinicalTrials.gov

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Hematologic MalignanciesMyelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNon-Hodgkin's LymphomaHodgkin's Disease
Interventions
DRUG

Sirolimus

DRUG

Tacrolimus

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00144703 - Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | Biotech Hunter | Biotech Hunter